| Study Name | Indication | Description | Location | Stipend | Apply |
|---|---|---|---|---|---|
| CA41705 | Lupus Nephritis | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS | Vandalia, Ohio | $1892 | Apply |
| AFFINITY (PSA2003) | Psoriatic Arthritis | A Phase 2a, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis | Vandalia, Ohio | $936 | Apply |
| SOLSTICE (PSA3005) | Psoriatic Arthritis | A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor [alpha] Agent | Vandalia, Ohio | $1300 | Apply |
| STAR (PSA4002) | Psoriatic Arthritis | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease | Vandalia, Ohio | $1300 | Apply |
| NEPTUNUS-01 | Sjogren's Syndrome | Vandalia, Ohio | $0 | Apply | |
| APEX (PSA3004) | Psoriatic Arthritis | A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis. | Springboro, Ohio | $1040 | Apply |